secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000920148-24-000096
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q2 revenue $3.22B (+6.2%), adj EPS $3.94; raises revenue guidance, boosts buyback $1B
--------------------------------------------------------------------------------

- Q2 revenue $3.22B (+6.2% YoY); diluted EPS $2.43 vs $1.74; adjusted EPS $3.94 vs $3.42.
- Free cash flow $432.9M vs $58.2M a year ago.
- Updated FY 2024 guidance: revenue growth 6.4%-7.5% (prior 4.8%-6.4%); adj EPS $14.30-$14.90 (incl. ~$0.40 Invitae dilution).
- Board approved $1.0B increase in share repurchase authorization to $1.4B; quarterly dividend $0.72/share.
- Invitae acquisition expected close early August; launched FDA-approved hemophilia B CDx and preeclampsia screening.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014824000096/0000920148-24-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014824000096/lh-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000920148-24-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer